Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon

Fer, Mehmet F.; Bottino, Gino C.; Sherwin, Stephen A.; Hainsworth, John D.; Abrams, Paul G.; Foon, Kenneth A.; Oldham, Robert K.

doi:10.1016/0002-9343(84)90550-3

Cited by 50 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 Corticosteroids have often been implicated in the pathogenesis of TLS probably because they are used as primary therapy for highly proliferating lymphoid disorders. 19 Less frequently, TLS has been reported after administration of intrathecal methotrexate 20 monoclonal antibodies (rituximab, gemtuzumab ozogamicin, campath), radiotherapy, interferon, thalidomide, hydroxyurea, fludarabine, imatinib, bortezomib, [21][22][23][24][25] and it has rarely been described also as a spontaneous event. 26 The Penn predictive score of tumor lysis syndrome (PPS-TLS) is a recently revised prognostic scoring system based on a single institution experience of 194 AML patients receiving induction chemotherapy.…”

Section: Recommendationsmentioning

confidence: 99%

Consensus conference on the management of tumor lysis syndrome

Tosi¹,

Barosi²,

Lazzaro³

et al. 2008

Haematologica

122

View full text Add to dashboard Cite

Tumor lysis syndrome is a potentially life threatening complication of massive cellular lysis in cancers. Identification of high-risk patients and early recognition of the syndrome is crucial in the institution of appropriate treatments. Drugs that act on the metabolic pathway of uric acid to allantoin, like allopurinol or rasburicase, are effective for prophylaxis and treatment of tumor lysis syndrome. Sound recommendations should regulate diagnosis and drug application in the clinical setting. The current article reports the recommendations on the management of tumor lysis syndrome that were issued during a Consensus Conference project, and which were endorsed by the Italian Society of Hematology (SIE), the Italian Association of Pediatric Oncologists (AIEOP) and the Italian Society of Medical Oncology (AIOM). Current concepts on the pathophysiology, clinical features, and therapy of tumor lysis syndrome were evaluated by a Panel of 8 experts. A consensus was then developed for statements regarding key questions on tumor lysis syndrome management selected according to the criterion of relevance by group discussion. Hydration and rasburicase should be administered to adult cancer patients who are candidates for tumor-specific therapy and who carry a high risk of tumor lysis syndrome. Cancer patients with a low-risk of tumor lysis syndrome should instead receive hydration along with oral allopurinol. Hydration and rasburicase should also be administered to patients with clinical tumor lysis syndrome and to adults and high-risk children who develop laboratory tumor lysis syndrome. In conclusion, the Panel recommended rasburicase for tumor lysis syndrome prophylaxis in selected patients based on the drug efficacy profile. Methodologically rigorous studies are needed to clarify its cost-effectiveness profile.

show abstract

Section: Recommendationsmentioning

confidence: 99%

Consensus conference on the management of tumor lysis syndrome

Tosi¹,

Barosi²,

Lazzaro³

et al. 2008

Haematologica

122

View full text Add to dashboard Cite

show abstract

“…Although most commonly seen following cytotoxic chemotherapy, other precipitating factors of TLS have been noted, including radiotherapy [7], corticosteroids [18], tamoxifen [2] and cytokine treatment [6]. Spontaneous TLS without the identification of any precipitating factors has occasionally been reported in Burkitt's lymphoma [9], acute myelogenous leukaemia [11], inflammatory breast carcinoma [17] and disseminated intra-abdominal adenocarcinoma of unknown primary [4].…”

Section: Discussionmentioning

confidence: 99%

Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours

Pentheroudakis

O'Neill

Vasey

et al. 2001

Support Care Cancer

View full text Add to dashboard Cite

Acute tumour lysis syndrome (TLS), a condition resulting from rapid destruction of tumour cells with massive release of cellular breakdown products, has been described following the treatment of various malignancies. However, spontaneous TLS has been described only rarely. Germ cell tumours (GCT) have a rapid cell turnover and often present with bulky metastatic disease. We report two cases of patients with metastatic GCT presenting with acute renal failure attributable to spontaneous TLS. All clinical and biochemical features of the syndrome were present. Both patients were treated with haemodialysis and intravenous administration of single-agent etoposide between dialysis sessions, resulting in recovery of renal function and marked decrease in tumour bulk within the first week after presentation. These cases are the first reported instances of spontaneous TLS in poor-risk metastatic GCT. Successful treatment with dialysis and chemotherapy is possible, and prophylactic vigorous hydration and allopurinol may be warranted in this setting.

show abstract

“…But there have been a few reports of TLS occurring after single-agent therapy with corticosteroids [5,6], fludarabine [7], amsacrine [8], tamoxifen [9], etoposide [10] and interferon [11], TLS with mitoxantrone, or other anthracyclines, however, has not been reported before.…”

Section: Discussionmentioning

confidence: 99%

“…Although TLS usually occurs after combination chemotherapy, there have been a few reports following single-agent che motherapy [5][6][7][8][9][10][11]. To the best of our knowl edge, however, this is the first case reported in the literature with an anthracycline, mitoxan trone, alone.…”

mentioning

confidence: 99%

Tumor Lysis Syndrome Following Single-Dose Mitoxantrone

Benekli¹,

Savaş²,

Güllü

et al. 1995

Chemotherapy

View full text Add to dashboard Cite

We report here a 16-year-old boy with pre-B-type acute lymphoblastic leukemia who developed acute tumor lysis syndrome (TLS) following 12 h mitoxantrone infusion. TLS is a distinct clinical entity which has been recognized most frequently with aggressive combination chemotherapy of rapidly proliferating hematologic neoplasms. There have been a few reports of single-agent-induced tumor lysis, but to our knowledge, this is the first case reported with mitoxantrone alone.

show abstract

Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon

Cited by 50 publications

References 15 publications

Consensus conference on the management of tumor lysis syndrome

Consensus conference on the management of tumor lysis syndrome

Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours

Tumor Lysis Syndrome Following Single-Dose Mitoxantrone

Contact Info

Product

Resources

About